This webinar will focus on the origin and biology of SARS-CoV-2, the virus responsible for the COVID-19 pandemic. More specifically, the featured speaker will detail how our immune system responds to infection, how variants such as Omicron emerge and the featured speaker will delineate the different outcomes that can result, including long COVID. The webinar will also be open to questions should you wish to discuss any other topics of interest relating to this virus.
Register for the webinar to learn everything that is presently known about this virus and the diseases it causes.
Benjamin tenOever, PhD, Professor of Microbiology and the Director of the Virus Research Institute, New York University
Dr. tenOever completed his postdoctoral training in Virology from Harvard after receiving his PhD in Medicine from McGill. He is presently a Professor of Microbiology and the Director of the Virus Research Institute at New York University. He is a Fulbright scholar and the recipient of a Presidential Award in Science and Engineering. Dr. tenOever’s research program focuses on the interactions between viruses and their hosts with a specific emphasis on SARS-CoV-2 in response to the COVID-19 pandemic. His lab is supported by the National Institute of Health, the Department of Defense, and the World Health Organization.
Who Should Attend?
This webinar is recommended for anyone interested in the biology underlying COVID-19. While the webinar will go into some scientific detail, in general, all efforts will be made to make the presentation accessible to everyone.
What You Will Learn
Join this webinar to:
- Learn the origin of SARS-CoV-2 and the nature of viruses in general
- Understand how the body initially responds to SARS-CoV-2 infection
- Gain insight into the molecular basis for long COVID
GenScript is the leading contract research organization in the world providing gene, peptide, protein, CRISPR, and antibody services. Since its foundation in 2002, GenScript has grown exponentially through partnerships with scientists conducting fundamental life science research, translational biomedical research, and early-stage pharmaceutical development. The company is recognized as having built a best-in-class capacity and capability for biological research services, encompassing gene synthesis, peptide synthesis, custom antibody and protein engineering, and in vitro and in vivo pharmacology – all with the goal to Make Research Easy.